DDInter1543 DDInter1676
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Protriptyline {u} (Compound) resembles {v} (Compound) Maprotiline
Protriptyline {u} (Compound) resembles {v} (Compound) Cyclobenzaprine
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Protriptyline {u} (Compound) binds {v} (Gene) CYP2D6
Protriptyline {u} (Compound) upregulates {v} (Gene) MAP7
Protriptyline {u} (Compound) downregulates {v} (Gene) NUP93
Protriptyline {u} (Compound) causes {v} (Side Effect) Parotid swelling
Protriptyline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Protriptyline (Compound) resembles Maprotiline (Compound)
Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Protriptyline (Compound) binds CYP2D6 (Gene)
Protriptyline (Compound) upregulates MAP7 (Gene)
Protriptyline (Compound) downregulates NUP93 (Gene)
Protriptyline (Compound) causes Parotid swelling (Side Effect)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Protriptyline may lead to a major life threatening interaction when taken with Pasireotide